Major scientific focus areas

- ART and mortality [9-11]
- Hepatitis coinfection [33-36]
- ART and CVD [20-21]
- Impact of DAA [37-39]
- Regional differences and quality of care [18, 40-45]
- Interruption of OI prophylaxis [27-28]
- ART and CKD [22]
- Biomarker research [47-50]


I-III
n = 7,315

IV*
  n = 1,225

V
  n = 1,223

VI
  n = 2,119

VII
  n = 2,458

VIII
  n = 2,259

IX
  n = 2,469

X**
  n = 3,985

Establishment of RESPOND (2017)

Data collection

- CVD
- Malignancies
- Renal function

Electronic data collection

Modular set-up
Figure 1: The EuroSIDA Study – scientific achievements, cohorts and data collection. Cohorts (enrolment waves) are indicated by roman numerals I-X. ART: antiretroviral therapy, CKD: chronic kidney disease, CVD: cardiovascular disease, HCV: hepatitis C virus, OI: opportunistic infections. * Inclusion of first sites in Eastern Europe. **Inclusion of only HIV/HCV coinfected people.